Targeting EZH2 functions

被引：0
|
作者：
Kleer, C. G.
机构：
来源：
CANCER RESEARCH | 2022年 / 82卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS21-ES13-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ES13-1
引用
收藏
页数：2
相关论文
共 50 条
  • [41] MiR-33a functions as a tumor suppressor in triple-negative breast cancer by targeting EZH2
    Zeng Weihua
    Zou Guorong
    Cao Xiaolong
    Li Weizhan
    Cancer Cell International, 20
  • [42] Precision Targeting with EZH2 and HDAC Inhibitors in Epigenetically Dysregulated Lymphomas
    Lue, Jennifer K.
    Prabhu, Sathyen A.
    Liu, Yuxuan
    Gonzalez, Yulissa
    Verma, Akanksha
    Mundi, Prabhjot S.
    Abshiru, Nebiyu
    Camarillo, JeannieM.
    Mehta, Swasti
    Chen, Emily I.
    Qiao, Changhong
    Nandakumar, Renu
    Cremers, Serge
    Kelleher, Neil L.
    Elemento, Olivier
    Amengual, Jennifer E.
    CLINICAL CANCER RESEARCH, 2019, 25 (17) : 5271 - 5283
  • [43] Targeting EZH2 and PRC2 dependence as novel anticancer therapy
    Xu, Bowen
    Konze, Kyle D.
    Jin, Jian
    Wang, Gang Greg
    EXPERIMENTAL HEMATOLOGY, 2015, 43 (08) : 698 - 712
  • [44] EZH2 in hepatocellular carcinoma: progression, immunity, and potential targeting therapies
    Bohan Wang
    Yachong Liu
    Zhibin Liao
    Haofeng Wu
    Bixiang Zhang
    Lei Zhang
    Experimental Hematology & Oncology, 12
  • [45] Inhibition of pancreatic cancer by targeting the epigenetic EZH2 complex.
    Lomberk, Gwen Alyce
    Mathison, Angela
    Missfeldt, Mckenna
    Salmonson, Ann
    Kossak, Sarah
    Buttar, Navtej
    Urrutia, Raul
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [46] EZH2 in hepatocellular carcinoma: progression, immunity, and potential targeting therapies
    Wang, Bohan
    Liu, Yachong
    Liao, Zhibin
    Wu, Haofeng
    Zhang, Bixiang
    Zhang, Lei
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2023, 12 (01)
  • [47] Targeting EZH2 for the treatment of hepatosplenic T-cell lymphoma
    Pikman, Yana
    Conway, Amy Saur
    Robichaud, Amanda L.
    Kitara, Samuel
    Church, Alanna J.
    Kennedy, Alyssa L.
    Silverman, Lewis B.
    Billett, Amy L.
    Weinstock, David M.
    Harris, Marian H.
    Stegmaier, Kimberly
    BLOOD ADVANCES, 2020, 4 (07) : 1265 - 1269
  • [48] Dual Targeting with EZH2 Inhibitor and STING Agonist to Treat Melanoma
    Al Emran, Abdullah
    Fisher, David E.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2022, 142 (04) : 1004 - 1006
  • [49] THERAPEUTIC TARGETING OF EZH2 AND BET BRD4 IN AT/RT
    Zhang, Ali
    Piunti, Andrea
    Ozark, Patrick
    He, Xingyao
    Katagi, Hiroaki
    Sasaki, Takahiro
    Laurie, Kathryn
    Goldman, Stewart
    Zou, Lihua
    Shilatifard, Ali
    Hashizume, Rintaro
    NEURO-ONCOLOGY, 2019, 21 : 63 - 63
  • [50] Naturally occurring anti-cancer agents targeting EZH2
    Shahabipour, Fahimeh
    Caraglia, Michele
    Majeed, Muhammed
    Derosa, Giuseppe
    Maffioli, Pamela
    Sahebkar, Amirhossein
    CANCER LETTERS, 2017, 400 : 325 - 335
12345